Foundation Medicine, Inc. (FMI) Appoints David J. Daly As Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of David J. Daly to the role of chief commercial officer. Mr. Daly brings more than 25 years of proven commercial experience in both emerging and Fortune 500 clinical diagnostics and oncology companies to his new role leading Foundation Medicine's commercial organization. Mr. Daly will report to president and chief executive officer, Michael J. Pellini, M.D.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.